Idenix Restructures Under Amended Deal With Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis will take over development, manufacture and commercialization of chronic hepatitis B therapy Tyzeka/Sebivo, pay worldwide royalties to Idenix.